Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `jetpack` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /var/www/wp-includes/functions.php on line 5835
August 2019 – Force Pharma Capital
Skip to content
Force Pharma Capital
Force Pharma Capital
Life Science Consulting, Business Development and Recruiting/Staffing
  • Home
  • About Us
  • Services
  • Pharmaceutical Blog
    • RLD
    • Excipients
    • Equipment
    • Health Technology
    • Regulatory Fees
  • Contact Us
  • FAQ
  • Portfolio

Month: August 2019

FDA warns test companies not to tell patients about gene-drug links – STAT

August 31, 2019 Blogger

The FDA is concerned that unsupported claims about gene-drug links could be dangerous, spurring patients to start, stop, or switch…

Continue Reading →

Posted in: Health Technology Filed under: FDA, technology

Certain Prostate Cancer Therapies Increase Risks for Patients with Pre-existing Heart Disease

August 28, 2019 Blogger

The effect of oral androgen signaling inhibitor therapies on patients with pre-existing cardiovascular disease may increase the risk of death.…

Continue Reading →

Posted in: Uncategorized Filed under: fixed dose combination

Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications | FDA

Blogger

The FDA is issuing an update regarding the ongoing efforts to resolve safety issues with ARB medications. — Read on…

Continue Reading →

Posted in: Uncategorized

Statement on the agency’s ongoing efforts to resolve safety issue with ARB medications | FDA

Blogger

The FDA is issuing an update regarding the ongoing efforts to resolve safety issues with ARB medications. — Read on…

Continue Reading →

Posted in: Uncategorized Filed under: gdufa

Drug Combination Leads to Effective Response, Remission in Patients with Multiple Myeloma

Blogger

Selinexor with dexamethasone effective in more than one-quarter of patients with multiple myeloma during a clinical trial. — Read on…

Continue Reading →

Posted in: Uncategorized Filed under: fixed dose combination, pdufa

FDA Approves Ixekizumab for Ankylosing Spondylitis Indication

Blogger

Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL is now approved for the treatment of active ankylosing spondylitis. — Read on…

Continue Reading →

Posted in: Uncategorized Filed under: approvals, pdufa

FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease | FDA

August 27, 2019 Blogger

FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease — Read on www.fda.gov/news-events/press-announcements/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-disease

Continue Reading →

Posted in: Uncategorized Filed under: approvals, fixed dose combination, pdufa

Drug Trials Snapshots: PRETOMANID | FDA

Blogger

Drug Trials Snapshots: PRETOMANID — Read on www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-pretomanid

Continue Reading →

Posted in: Uncategorized Filed under: approvals, fixed dose combination

Enterovirus infection linked to acute flaccid myelitis | National Institutes of Health (NIH)

Blogger

Evidence of infection with an enterovirus was found in about 80% of people with the rare but serious condition called…

Continue Reading →

Posted in: Uncategorized

Vegetable-Based Diet Leads to Lower Fatigue in Patients with Multiple Sclerosis

Blogger

Patients with progressive multiple sclerosis who were placed on the Wahls diet, which is high in fruits and vegetables, found…

Continue Reading →

Posted in: Health Technology Filed under: technology

Post navigation

Page 1 of 3
1 2 3 Next →

Recent Posts

  • Most Recent Changes to the IID Database | FDA
  • The History, Benefits of Pharmaceutical REMS Programs
  • FDA approves first drug for treatment of peanut allergy for children

Recent Comments

  • flower bouquet delivery online on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma
  • cheap flowers online same day delivery on Trending News Today: Investigational Long-Acting HIV Injection Shows Efficacy in Study
  • flower arrangements for baby shower girl on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Archives

  • August 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • November 2018

Follow Us

Contact Us

  • Email
    forcepharma@icloud.com
  • Phone
    732-702-1824
  • Address
    265 Route 34 Lower Level, Colts Neck, New Jersey, 07722
Copyright © 2018 Force Pharma Capital